Notice2021-18664
Certain Microfluidic Systems and Components Thereof and Products Containing Same; Notice of the Commission's Determination To Institute a Rescission Proceeding; To Rescind Permanently a Limited Exclusion Order and a Cease and Desist Order; Termination of Rescission Proceeding
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 30, 2021
Issuing agencies
International Trade Commission
Abstract
Notice is hereby given that the U.S. International Trade Commission has determined to institute a rescission proceeding, rescind the remedial orders issued in the underlying investigation, and to terminate the rescission proceeding.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 165 (Monday, August 30, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 165 (Monday, August 30, 2021)]
[Notices]
[Pages 48441-48442]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-18664]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation N. 337-TA-1100 (Rescission)]
Certain Microfluidic Systems and Components Thereof and Products
Containing Same; Notice of the Commission's Determination To Institute
a Rescission Proceeding; To Rescind Permanently a Limited Exclusion
Order and a Cease and Desist Order; Termination of Rescission
Proceeding
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined to institute a rescission proceeding, rescind
the remedial orders issued in the underlying investigation, and to
terminate the rescission proceeding.
FOR FURTHER INFORMATION CONTACT: Benjamin S. Richards, Esq., Office of
the
[[Page 48442]]
General Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 708-5453. Copies of non-
confidential documents filed in connection with this investigation may
be viewed on the Commission's electronic docket (EDIS) at <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>. For help accessing EDIS, please email
<a href="/cdn-cgi/l/email-protection#a9ecede0fa9ae1ccc5d9e9dcdac0ddca87cec6df"><span class="__cf_email__" data-cfemail="c782838e94f48fa2abb787b2b4aeb3a4e9a0a8b1">[email protected]</span></a>. General information concerning the Commission may
also be obtained by accessing its internet server at <a href="https://www.usitc.gov">https://www.usitc.gov</a>. Hearing-impaired persons are advised that information on
this matter can be obtained by contacting the Commission's TDD terminal
on (202) 205-1810.
SUPPLEMENTARY INFORMATION: On February 21, 2018, the Commission
instituted this investigation based on a complaint filed by 10X
Genomics, Inc. of Pleasanton, CA (``10X''). 83 FR 7491 (Feb. 21, 2018).
The complaint alleged violations of section 337 of the Tariff Act of
1930, as amended, 19 U.S.C. 1337, in the importation into the United
States, the sale for importation, or the sale within the United States
after importation of certain microfluidic systems and components
thereof and products containing same by reason of infringement of one
or more claims of U.S. Patent Nos. 9,644,204 (``the '204 patent'');
9,689,024 (``the '024 patent''); 9,695,468 (``the '468 patent''); and
9,856,530 (``the '530 patent''). Id. The Commission's notice of
investigation named as the sole respondent Bio-Rad Laboratories, Inc.
of Hercules, CA (``Bio-Rad''). Id. The Office of Unfair Import
Investigations (``OUII'') is participating in this investigation. Id.
On July 12, 2019, the presiding administrative law judge issued the
final initial determination (``ID''). The ID found a violation of
section 337 by virtue of Bio-Rad's indirect infringement of the '024,
the '468, and the '530 patents. The ID found that 10X had not
established a violation with respect to the '204 patent. On October 17,
2019, the Commission determined to review various findings in the ID.
Following its review, on February 12, 2020, the Commission found a
violation of section 337 with respect the '024 patent; the '468 patent;
and the '530 patent. 85 FR 9479 (Feb. 19, 2020). The Commission also
found no violation of section 337 with respect to the '204 patent.
Having found a violation of section 337, and upon consideration of
the statutory public interest factors, the Commission determined to
issue a limited exclusion order prohibiting further importation of Bio-
Rad's infringing microfluidic systems and a cease and desist order
against Bio-Rad. Id. On April 29, 2021, in an appeal initiated by Bio-
Rad, the U.S. Court of Appeals for the Federal Circuit affirmed the
Commission's final determination. Bio-Rad Laboratories, Inc. v. Int'l
Trade Comm'n, 996 F.3d 1302 (Fed. Cir. 2021).
On July 26, 2021, 10X and Bio-Rad entered into a settlement
agreement that resolved the disputes concerning the subject matter of
this investigation. Thereafter, on July 28, 2021, 10X and Bio-Rad
jointly petitioned for rescission of the Commission's remedial orders
under 19 U.S.C. l337(k) and Commission Rule 210.76(a) (19 CFR
210.76(a)). On August 9, 2021, OUII filed a response in support of 10X
and Bio-Rad's rescission petition.
The Commission has determined that the petition complies with
Commission rules, see 19 CFR 210.76(a)(3), and that there are no
extraordinary reasons to deny rescission of the remedial orders.
Accordingly, the Commission has determined to institute a rescission
proceeding and to permanently rescind the LEO and the CDO. The
rescission proceeding is hereby terminated.
The Commission's vote on this determination took place on August
25, 2021.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in part 210 of the Commission's Rules of Practice and Procedure (19 CFR
210).
By order of the Commission.
Issued: August 25, 2021.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2021-18664 Filed 8-27-21; 8:45 am]
BILLING CODE 7020-02-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 30, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.